8-K: Health In Tech Faces Nasdaq Listing Scrutiny

Health In Tech, Inc. received notices from Nasdaq regarding non-compliance with independent director and minimum bid price requirements, with cure periods granted.

Summary

• Health In Tech, Inc. received two letters from Nasdaq on October 14, 2026, and October 12, 2026, respectively.
• The first letter indicates non-compliance with Nasdaq's independent director and audit committee requirements due to a board member's resignation.
• The company has until its next annual shareholders meeting (scheduled for November 10, 2026) or February 8, 2027, to regain compliance with director requirements.
• The second letter indicates non-compliance with the minimum $1.00 bid price requirement for continued listing, as the stock has closed below this for 30 consecutive business days.
• The company has until April 12, 2027, to regain compliance with the bid price requirement, potentially through a reverse stock split.
• Both letters have no immediate effect on the listing or trading of the company's Class A common stock on The Nasdaq Capital Market.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a negative sentiment due to the company facing potential delisting from Nasdaq for failing to meet continued listing requirements, despite having cure periods.

Positives

• The company has been granted cure periods by Nasdaq to regain compliance with listing rules.
• The company intends to regain compliance with independent director and audit committee requirements at its upcoming annual shareholders meeting on November 10, 2026.
• The company is actively monitoring its stock price and considering options, including a reverse stock split, to meet the bid price requirement.

Negatives

• The company is not in compliance with Nasdaq's independent director and audit committee requirements.
• The company is not in compliance with Nasdaq's minimum $1.00 bid price requirement for continued listing.
• There is a risk of delisting if compliance is not achieved within the specified cure periods.
• The company's Class A common stock has been trading below $1.00 for 30 consecutive business days.

Risks

• Failure to regain compliance with Nasdaq's independent director and audit committee requirements by the earlier of the next annual shareholders meeting or February 8, 2027.
• Failure to regain compliance with Nasdaq's minimum $1.00 bid price requirement by April 12, 2027.
• Potential delisting from The Nasdaq Capital Market if compliance is not achieved.
• The possibility that Nasdaq may not grant any relief from delisting or that the company may not be able to meet Nasdaq's requirements for such relief.
• The company may need to effect a reverse stock split to regain compliance with the bid price rule, which could have its own implications.

Future Outlook

The company intends to regain compliance with Nasdaq's independent director and audit committee requirements at its upcoming annual shareholders meeting on November 10, 2026, by electing a new independent director. The company will monitor its stock's closing bid price and consider options, including a reverse stock split, to comply with the minimum bid price rule by April 12, 2027. Eligibility for an additional 180-day compliance period is also mentioned as a possibility.

Management Comments

• The Company intends to regain compliance with both Nasdaq Listing Rules discussed above following the Company's next annual shareholders meeting, which is scheduled to take place on November 10, 2026 (the 2026 Annual Meeting), and at which the Company expects a new independent director nominee will be elected to the Board and thereafter appointed to the Audit Committee.
• The Company intends to monitor the closing bid price of its Class A common stock and consider available options if its Class A common stock does not trade at a level likely to result in the Company regaining compliance with Nasdaq's minimum bid price rule by April 12, 2027, which could include effecting a reverse stock split.

Industry Context

StockSavvy.ai notes that Nasdaq listing requirements, particularly regarding independent directors and minimum bid prices, are common hurdles for publicly traded companies. Companies often face these challenges during periods of market volatility or operational difficulties, and the path to regaining compliance can involve strategic corporate actions like board restructuring or reverse stock splits.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for share price volatility and risk of delisting, which could reduce liquidity and investor confidence.
• Creditors: Increased risk if delisting leads to financial instability.
• Employees: Potential impact on morale and job security if delisting occurs.

Next Steps

• Elect a new independent director nominee at the 2026 Annual Meeting on November 10, 2026, and appoint them to the Audit Committee.
• Monitor the closing bid price of Class A common stock.
• Consider available options, including a reverse stock split, to regain compliance with the minimum bid price rule by April 12, 2027.
• If necessary, provide Nasdaq Staff with written notice of intent to cure the deficiency during a potential second compliance period.
• Potentially effect a reverse stock split if required for compliance.

Key Dates

Recommendation

The company is facing significant Nasdaq listing challenges, including non-compliance with independent director and bid price rules, which poses a material risk of delisting. While cure periods are provided and management intends to address these issues, the uncertainty surrounding successful compliance and the potential need for a reverse stock split warrants a cautious 'hold' stance until compliance is demonstrated.

Keywords

Nasdaq compliance, Listing requirements, Bid price, Independent directors, Audit committee, Delisting risk, Cure period, Reverse stock split